Immune effector cell therapies, including Chimeric Antigen Receptor T Cell Therapy (CAR-T), are an exciting new therapeutic intervention for certain malignancies. This innovative cancer treatment contributes to our existing repertoire of immunotherapy and is integral to the concept of personalised medicine.

The study day will give delegates the opportunity to explore the current immunotherapy landscape and the role of CAR-T as a systemic anti cancer therapy. The day will raise awareness of the complex patient pathway and the challenges experienced by patients, carers and the wider MDT.